Great event talking about early detection and interception, innovation, biomarkers and the future of life science investment with Geoff Taylor Oxnard and Julie Gerberding, CEO of ⁦Foundation for the National Institutes of Health⁩

While liquid biopsy become one of the pillar of cancer management, we aimed at getting an insight on the mechanics behind ctDNA shed and tumor fraction
Benjamin Besse Fabrice Barlesi Geoff Oxnard MD Foundation Medicine Gustave Roussy ESMO - Eur. Oncology

Great working together to advance our understandings of ctDNA in cancer! Geoff Oxnard MD Christian Rolfo

Nine years ago I was told I had cancer. #lungcancer #bestlife EGFR Resisters Geoff Oxnard MD

Pt w/out measurable disease via RECIST often excluded from trial - discussion re:ctDNA & trial design that considers orthogonal patient populations (ctDNA-, disease measurable pts) and other thoughts prostate/breast w difficult to measure boney disease Friends of Cancer Research Geoff Oxnard MD

It was an honour to speak at the Intl Symposium on Precision Oncology at Kokilaben Hospital, Navi Mumbai
#Multiomics is the way forward 🧬🎗️🧫🩻🔬💊
bhawna sirohi Umut. Dişel Nirmal Raut Ryan T. Scott Aastha Geoff Oxnard MD Anguraj Sadanandam Kurt Van der Speeten Ben Westphalen Dr. Birep Aygün

Lung cancer is largely a radiographic diagnosis. Ordering liquid bx prior to tissue confirmation accelerates timeline to treatment. Important for early and late stage disease. Thank you for the great collaboration! Geoff Oxnard MD Christian Rolfo Bruna Pellini, MD #ngs #liquidbiopsy

We welcome Prof Geoff Oxnard as our international keynote for TAS2023! He will be presenting on the diagnostic power and clinical applications of ctDNA to guide precision oncology.
For more info & registration visit: liquidbiopsy.org.au
Geoff Oxnard MD
#liquidbiopsy
#TAS2023

A new study shows:
Early use of liquid biopsy 🩸🧬🩸🧬before diagnosis can speed up genomic profiling & treatment for advanced non-small-cell lung cancer patients.
ASCO Christian Rolfo Geoff Oxnard MD International Society of Liquid Biopsy OncoAlert
doi.org/10.1200/PO.23.…

Work and fun! An intense 4-day trip to Tokyo (Lilly Japan, Geoff Oxnard MD ), Shanghai (Dr. Caicun Zhou), Hangzhou (Dr. Yang Xia), Tokyo (@HHorinouchi) with international colleagues and biotech partners.

Liquid Biopsy (LBx) of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment. Our analysis of a large database further reinforce the clinical utility of early LBx use in pts with suspected lung cancer. Christian Rolfo Geoff Oxnard MD Lincoln Pasquina

Lung Cancer Webinar moderated by @hatimhusainMD and discussants Joel W. Neal, MD, PhD @standfordMed and Geoff Oxnard MD #BostonMedCenter on #MolecularDiagnostics in #NSCLC liquid and Tissue NGS. Sponsored by AstraZenecaUS
View here youtu.be/UzVVOiDsWqA

🚨New publication alert❗️

🚨Published in JTO & JTO CRR, the phenomenal Julia Rotow MD Geoff Oxnard MD Alexa Schrock and team dissect the Real-World Genomic Profile of #EGFR Second-site Mutations & other Osimertinib Resistance Mechanisms in #NSCLC 👏👏👏

Link ⏬:
jto.org/article/S1556-…

⭐️ ctDNA testing during induction chemo IO

📍Identifies patients at higher riskf or disease progression

📍 May inform pts selection for novel personalized
maintenance or 2-line treatment strategies

Bruna Pellini, MD , Geoff Oxnard MD , Mark socinski &
all research members

Fantastic recorded presentation by Geoff Oxnard MD this morning at #TAS2023 with a special mention to Omico Australia and Professor DM Thomas MoST #clinicaltrials using #ctDNA to detect changes through plasma following radiological progression. #liquidbiopsy #InformedDecisionMaking

Liquid biopsy first approach in non-small cell #LungCancer #LCSM by Dr. Jeffrey Ross Foundation Medicine at Italian Summit on #PrecisionMedicine G Curigliano MD PhD OncoAlert Geoff Oxnard MD Christian Rolfo

“The problem with RECIST is we ignore all of those measurable patients.” Geoff Oxnard MD from
Foundation Medicine discussing ctMoniTR Module 1 results.

Join live: focr-org.zoom.us/j/81133154006

#ctDNAFriends

Next week at the Friends of Cancer Research Public Meeting – join Foundation Medicine’s Geoff Oxnard MD, SVP, Clinical Development for the session “Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI (ctMoniTR Module 1)”: bit.ly/3pxoB5c

Don’t miss tomorrow’s Friends of Cancer Research meeting on advancements in circulating tumor DNA, featuring a panel with Foundation Medicine's own Dr. Geoff Oxnard MD

Discussion on new technologies and lung cancer has to include equitable and universal access to these new technologies #NYLCF23 chadi nabhan MD, MBA, FACP Geoff Oxnard MD Max Diehn, MD/PhD New York Lung Cancer Foundation